Dickkopf-related protein 3 (DKK3) predicts AKI

Presswire, 16 June 2019

Acute kidney injury (AKI) is a common complication after cardiac surgery. The severity fluctuates from subclinical AKI, an increase in biochemical markers of kidney injury, to severe AKI requiring renal replacement therapy with dialysis.

Nephrology and Public Policy Committee (NPPC) aims to intensify research activity

Presswire, 16 June 2019

Epidemiological and clinical research and public policy in Europe are generally considered to be comprehensive and successful – and the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) is playing a key role in the field of nephrology research.

Indigestion remedy significantly slows kidney function decline and improves survival in late-stage CKD

Presswire, 16 June 2019

As chronic kidney disease (CKD) progresses, the kidneys become less able to maintain a healthy balance of acids in the body, a condition known as metabolic acidosis.

Maintaining work during the final 6 months prior to haemodialysis was associated with a better survival

Presswire, 16 June 2019

 26% of patients had been employed 6 months prior to dialysis initiation – but this dropped to 15% when dialysis treatment was initiated.

Linagliptin improved albuminuria but had no effect on eGFR and CV risk in patients with diabetes

Presswire, 16 June 2019

In the CARMELINA trial nearly 10% of all patients with diabetes had nephrotic-range proteinuria at baseline. This was associated with a high incidence of cardiovascular/kidney disease but this secondary disease burden could not be lowered by linagliptin.

Benefits beyond fracture risk reduction? Results of the VITALE study

Presswire, 16 June 2019

Kidney transplantation is the treatment of choice for most people with kidney failure, as it will improve their survival while increasing their quality of life compared to remaining on dialysis.

Clinical trials and research priorities in dialysis Patients: Time for a new approach?

Presswire, 13 June 2019

Historically, the number of RCTs performed in the ESRD population has been very low compared to other medical subspecialties. Furthermore, several of the few large RCTs conducted in patients with ESRD have yielded inconclusive or negative results, dampening enthusiasm for future investment in similar trials.

PCSK9 inhibitors: Specific studies are mandatory to prove efficacy and safety in CKD

Presswire, 13 June 2019

High cardiovascular morbidity and mortality remain a persisting problem in patients with CKD. Many efforts have been made in subjects with normal kidney function to prevent and to reduce the progression of cardiovascular diseases.

Still an unmet need: New therapeutic targets in Alport syndrome

Presswire, 13 June 2019

Alport syndrome (AS) is a hereditary type IV collagen disease that leads to progressive proteinuria, renal fibrosis, and kidney failure.

Enhesa Appoints Peter Schramme as New CEO to Drive Market Expansion

Presswire, 13 June 2019

Enhesa, the leading global content provider for environmental, health and safety (EHS) regulatory compliance, announced Peter Schramme as its new Chief Executive Officer (CEO).

Pages

Subscribe to Greatreporter RSS